Lotus Pharmaceutical Co (美時化學製藥), which makes and distributes oral and injected medicine, yesterday said its future parent company Alvogen Inc spent US$187 million to acquire South Korean-based Dream Pharma Ltd, which is to be put under Lotus’ control once the deal is approved.
The US-based Alvogen, which makes generic drugs and biosimilars, plans to acquire the company through its South Koran subsidiary Kunwha Pharmaceutical Co, and the deal is still pending approval from the South Korean government, Lotus said.
Alvogen expects the deal to be completed in the fourth quarter of this year. The deal would make Kunwha the largest generic drug maker in South Korea, Lotus said.
The acquisition should strengthen Kunwha’s retail routes in South Korea and increase Kunwha’s product portfolio because the two companies sell different products, and Alvogen is set to sell its products to Taiwan and other markets in Asia using Alvogen’s networks, Lotus said.
“[The Asia-Pacific region] is one of the fastest-growing regions globally for generic pharmaceuticals. The market remains very fragmented, which provides an excellent opportunity for Alvogen to play a leading role in further industry consolidation,” Alvogen said in its statement yesterday.
Dream Pharma, a subsidiary of Hanwha Chemical Corp, which makes polyethylene, polyvinyl chloride plasticizer and base chemicals, reported revenue of about US$100 million last year, with 56 percent of that from sales of weight-loss drugs, Lotus said.
With 100 drugs currently in the pipeline, Dream Pharma accounts for 35 percent of the South Korean weight-loss drug market, according to Lotus.
“Dream Pharma is not a core business for Hanwha, and we believe we can increase its profit by adjusting Dream Pharma’s structure after acquiring it,” Lotus vice president Hung Yao-le (洪堯樂) said by telephone yesterday.
Alvogen is to spend US$200 million to acquire 67 percent of Lotus’ shares on Aug. 12, and Lotus also plans to spend US$180 million to seize 100 percent of South Korea-based Alvogen Korea and other Asian subsidiaries of Alvogen, Lotus said.
After Lotus acquired Alvogen Korea, Lotus would have a 67 percent stake in Kunwha, which posted a revenue of about US$80 million last year, Lotus said.
Both Dream Pharma and Kunwere in the black for last year, Hung said.
On Tuesday, US President Donald Trump weighed in on a pressing national issue: The rebranding of a restaurant chain. Last week, Cracker Barrel, a Tennessee company whose nationwide locations lean heavily on a cozy, old-timey aesthetic — “rocking chairs on the porch, a warm fire in the hearth, peg games on the table” — announced it was updating its logo. Uncle Herschel, the man who once appeared next to the letters with a barrel, was gone. It sparked ire on the right, with Donald Trump Jr leading a charge against the rebranding: “WTF is wrong with Cracker Barrel?!” Later, Trump Sr weighed
HEADWINDS: Upfront investment is unavoidable in the merger, but cost savings would materialize over time, TS Financial Holding Co president Welch Lin said TS Financial Holding Co (台新新光金控) said it would take about two years before the benefits of its merger with Shin Kong Financial Holding Co (新光金控) become evident, as the group prioritizes the consolidation of its major subsidiaries. “The group’s priority is to complete the consolidation of different subsidiaries,” Welch Lin (林維俊), president of the nation’s fourth-largest financial conglomerate by assets, told reporters during its first earnings briefing since the merger took effect on July 24. The asset management units are scheduled to merge in November, followed by life insurance in January next year and securities operations in April, Lin said. Banking integration,
LOOPHOLES: The move is to end a break that was aiding foreign producers without any similar benefit for US manufacturers, the US Department of Commerce said US President Donald Trump’s administration would make it harder for Samsung Electronics Co and SK Hynix Inc to ship critical equipment to their chipmaking operations in China, dealing a potential blow to the companies’ production in the world’s largest semiconductor market. The US Department of Commerce in a notice published on Friday said that it was revoking waivers for Samsung and SK Hynix to use US technologies in their Chinese operations. The companies had been operating in China under regulations that allow them to import chipmaking equipment without applying for a new license each time. The move would revise what is known
Artificial intelligence (AI) chip designer Cambricon Technologies Corp (寒武紀科技) plunged almost 9 percent after warning investors about a doubling in its share price over just a month, a record gain that helped fuel a US$1 trillion Chinese market rally. Cambricon triggered the selloff with a Thursday filing in which it dispelled talk about nonexistent products in the pipeline, reminded investors it labors under US sanctions, and stressed the difficulties of ascending the technology ladder. The Shanghai-listed company’s stock dived by the most since April in early yesterday trading, while the market stood largely unchanged. The litany of warnings underscores growing scrutiny of
RSS